{"filing":{"accession_number":"0001725160-26-000052","cik":"0001725160","ticker":"ZNTL","company_name":"Zentalis Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-06-18","report_date":null,"primary_document":"zntl-20260616.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516026000052/zntl-20260616.htm"},"events":[{"id":11798,"run_id":10377,"accession_number":"0001725160-26-000052","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear disclosure of shareholder voting results from Zentalis Pharmaceuticals' June 16, 2026 Annual Meeting of Stockholders. The filing reports the outcomes of three proposals: election of two Class III directors (David Johnson and Jan Skvarka, Ph.D.), ratification of Ernst \u0026 Young LLP as independent auditor, and advisory approval of named executive officer compensation. All three items passed. This is a routine but material disclosure required under Item 5.07 of Form 8-K.","company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","filing_date":"2026-06-18","form":"8-K","submitted_at":null,"items":[{"id":8476,"accession_number":"0001725160-26-000052","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from Zentalis Pharmaceuticals' June 16, 2026 Annual Meeting of Stockholders. The filing reports the outcomes of three proposals: election of two Class III directors (David Johnson and Jan Skvarka, Ph.D.), ratification of Ernst \u0026 Young LLP as independent auditor, and advisory approval of named executive officer compensation. All three items passed. This is a routine but material disclosure required under Item 5.07 of Form 8-K.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T20:04:50.523022+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8476,"accession_number":"0001725160-26-000052","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from Zentalis Pharmaceuticals' June 16, 2026 Annual Meeting of Stockholders. The filing reports the outcomes of three proposals: election of two Class III directors (David Johnson and Jan Skvarka, Ph.D.), ratification of Ernst \u0026 Young LLP as independent auditor, and advisory approval of named executive officer compensation. All three items passed. This is a routine but material disclosure required under Item 5.07 of Form 8-K.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T20:04:50.523022+00:00","company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","filing_date":"2026-06-18"}]}